Cover Image
市場調查報告書

慢性脫髓鞘多發性神經炎 (CIDP) :開發中產品分析

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 328617
出版日期 內容資訊 英文 55 Pages
訂單完成後即時交付
價格
Back to Top
慢性脫髓鞘多發性神經炎 (CIDP) :開發中產品分析 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline Review, H2 2017
出版日期: 2017年08月16日 內容資訊: 英文 55 Pages
簡介

慢性脫髓鞘多發性神經炎 (CIDP)是造成惡化型四肢肌肉無力及感覺障礙的神經疾病。這個疾病是由於末梢神經的髓磷脂鞘損壞所引起。會出現四肢中心及末端部位的衰弱(初期症狀),站起時暈眩、手腳疼痛、麻痺等症狀。

本報告提供全球治療慢性脫髓鞘多發性神經炎 (CIDP) 所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

簡介

  • 調查範圍

慢性脫髓鞘多發性神經炎 (CIDP) 概要

治療藥的開發

  • 開發中產品的概要

慢性脫髓鞘多發性神經炎 (CIDP) :企業開發中的治療藥

慢性脫髓鞘多發性神經炎 (CIDP) :開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

慢性脫髓鞘多發性神經炎 (CIDP) :企業開發中的產品

慢性脫髓鞘多發性神經炎 (CIDP) 的治療藥的開發企業

  • Baxalta Incorporated
  • CSL Limited
  • GeNeuro SA
  • 田邊三菱製藥
  • Pfizer Inc.
  • TEIJIN FIBERS製藥
  • 慢性脫髓鞘多發性神經炎 (CIDP) :治療藥的評估
  • 單劑產品
  • 組合產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • GL-2045
  • GNbAC-1
  • immune globulin (human)
  • immune globulin (human)
  • immune globulin (human)

慢性脫髓鞘多發性神經炎 (CIDP) :最近的開發平台趨勢

慢性脫髓鞘多發性神經炎 (CIDP) :暫停中的計劃

慢性脫髓鞘多發性神經炎 (CIDP) :產品開發的里程碑

  • 關注的新聞和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9618IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline Review, H2 2017, provides an overview of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (Central Nervous System) pipeline landscape.

Chronic inflammatory demyelinating polyneuropathy (CIDP) also called as chronic relapsing polyneuropathy is a neurological disorder characterized by progressive weakness and impaired sensory function in the legs and arms. The disease is caused by damage to the myelin sheath of the peripheral nerves. Symptoms include initial limb weakness, both proximal and distal, orthostatic dizziness, tingling and numbness of hands and feet.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 1, 3, 2, 1 and 1 respectively.

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (Central Nervous System)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Overview
    • Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Products under Development by Companies
  • Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Companies Involved in Therapeutics Development
    • CSL Ltd
    • GeNeuro SA
    • MedDay SA
    • Octapharma AG
    • Pfizer Inc
    • Shire Plc
    • Teijin Pharma Ltd
  • Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Drug Profiles
    • biotin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GL-2045 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GNbAC-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • hyaluronidase (recombinant, human) + immune globulin (human) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • immune globulin (human) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • immune globulin (human) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • immune globulin (human) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • immune globulin (human) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Dormant Projects
  • Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Discontinued Products
  • Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Product Development Milestones
    • Featured News & Press Releases
      • Jul 19, 2017: FDA Accepts CSL Behrings Supplemental Biologics License Application for Hizentra Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Indication
      • Jul 11, 2017: CSL Behring Awards Researchers to Advance Immunoglobulin Therapy in Treating Neurological Disorders
      • Mar 01, 2017: CSL Behring Announces Largest Ever CIDP Clinical Study Completed
      • Feb 14, 2017: FDA Accepts CSL Behring's Biologics License Application Supplement for Using Privigen to Treat Chronic Inflammatory Demyelinating Polyneuropathy, a Rare Neurological Condition
      • Aug 10, 2015: Gliknik Licensee Pfizer Receives Orphan Drug Designation From U.S. Food and Drug Administration for Drug Candidate Directed Towards Rare Neurological Disorder
      • Apr 04, 2013: CSL Behring's Privigen Obtains European Approval For Treatment Of Chronic Inflammatory Demyelinating Polyneuropathy
      • Feb 21, 2013: CHMP Adopts Positive Opinion Recommending Variation To Terms Of Marketing Authorization For CSL Behring's Privigen
      • Jun 27, 2012: PRIMA Study Shows Treatment With Privigen Improved Function In Patients With Chronic Inflammatory Demyelinating Polyneuropathy
      • May 30, 2012: CSL Behring Submits Marketing Authorization Variation Application To EMA For Privigen In Chronic Inflammatory Demyelinating Polyradiculoneuropathy
      • Mar 26, 2012: CSL Behring Enrolls First Patient In PATH Trial To Evaluate Hizentra For Treatment Of CIDP
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline by CSL Ltd, H2 2017
  • Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline by GeNeuro SA, H2 2017
  • Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline by MedDay SA, H2 2017
  • Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline by Octapharma AG, H2 2017
  • Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline by Pfizer Inc, H2 2017
  • Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline by Shire Plc, H2 2017
  • Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline by Teijin Pharma Ltd, H2 2017
  • Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Dormant Projects, H2 2017
  • Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products by Targets, H2 2017
  • Number of Products by Stage and Targets, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top